This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Symptom control - use of analgesics and NSAIDs

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Symptomatic treatment of rheumatoid arthritis is primarily achieved through the use of non-steroidal anti-inflammatory drugs. There may be the need for a further drug, e.g. paracetamol, to be used specifically as an analgesic.

If there are acute exacerbation, or chronic active disease that is difficult to control, then there may be a role for short-term corticosteroid therapy in symptomatic management.

NICE state that (1):

  • consider oral non-steroidal anti-inflammatory drugs (NSAIDs, including traditional NSAIDs and cox II selective inhibitors), when control of pain or stiffness is inadequate
    • take account of potential gastrointestinal, liver and cardio-renal toxicity, and the person's risk factors, including age and pregnancy

  • when treating symptoms of RA with oral NSAIDs: offer the lowest effective dose for the shortest possible time offer a proton pump inhibitor (PPI), and review risk factors for adverse events regularly

  • if a person with RA needs to take low-dose aspirin, healthcare professionals should consider other treatments before adding an NSAID (with a PPI) if pain relief is ineffective or insufficient

If NSAIDs or COX-2 inhibitors are not providing satisfactory symptom control, review the disease-modifying or biological drug regimen

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.